The Food and Drug and Administration (FDA) has given its endorsement to the license application review from Merck & Co., Inc. (NYSE:MRK) and its Danish biotech research partner ALK-Abelló on MK-8237 for dust mite allergies.

The two companies have been seeking a license for MK-8237, a house dust mite SLIT-tablet for the treatment of allergic rhinitis with or without conjunctivitis. Patients are exposed to progressively increasing levels of house dust mite allergen which in return trains the immune system to restrain from allergic reactions and symptoms are significantly reduced.

This is not the first approval for the two. They already obtained FDA’s approval for a grass allergy immunotherapy called Grastek in addition to the ragweed allergy treatment Ragwitek. The two drugs have had steep competition in their sales with Ragwitek hovering at around $300 million while Grastek has $150 million. Nevertheless, Merck’s allergy franchise is likely to outdo these records in the event it gains approval of its MK-8237 given that dust mites are a such a common allergy.

The BLA for the drug has received immense support from the late-stage trials which have given top-line results that have indicated a significant fall of patients’ risks of moderate to severe asthma exacerbations.

The Phase IIb study involved 124 patients with house dust mite-induced allergic rhinitis. The use of MK-8237 improved 24-week nasal symptoms by 49% having been administered at its highest dosage. Its efficacy was measured by charting itchy nose, ocular irritation, blocked nose, throat irritation and oral swelling.

VP of clinical research at Merck Research Laboratories, Stuart Green has applauded the latest of Merck’s efforts and commitment to helping patients with allergies. Being a potential new option for adults, the clinical development of MK-8237 is an important milestone.

ALK estimates indicate that one out of 10 adults in Europe suffers from allergic rhinitis. Nonetheless, the drug which has gained approval in 11 European countries is also helpful to asthmatics since those who have house dust mites (HDM) allergic asthma also have allergic rhinitis.

POPULAR CATEGORY

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions.
At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices.
Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.